Zhejiang Huahai Pharmaceutical Co Ltd (600521):企業の財務・戦略的SWOT分析

◆英語タイトル:Zhejiang Huahai Pharmaceutical Co Ltd (600521) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12929
◆発行会社(調査会社):GlobalData
◆発行日:2019年1月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Zhejiang Huahai Pharmaceutical Co Ltd (600521) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Zhejiang Huahai Pharmaceutical Co Ltd (Huahai Pharmaceuticals) is a pharmaceutical company that carries out the research, production and sale of formulations, active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company also offers technology services. It provides pharmaceutical products in cardiovascular, central nervous system (CNS), metabolic disorders, infectious disease, women’s health and ophthalmology therapy areas. Huahai Pharmaceuticals has established domestic marketing network in compliance with GSP standards, with formulations covering several provinces and municipals of China. Operating through subsidiaries in the US and China, the company distributes its products to several countries worldwide. Huahai Pharmaceuticals is headquartered in Zhejiang, China.

Zhejiang Huahai Pharmaceutical Co Ltd Key Recent Developments

Dec 11,2018: FDA issues warning letter to Zhejiang Huahai Pharmaceutical involved in valsartan recall
Nov 29,2018: USFDA issues Warning Letter to Zhejiang Huahai Pharmaceutical
Oct 15,2018: EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU Share
Oct 02,2018: Information update – Health Canada finds Zhejiang Huahai Pharmaceuticals site non-compliant with requirements for the manufacture of drug ingredients
Sep 13,2018: Update on review of valsartan medicines

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Zhejiang Huahai Pharmaceutical Co Ltd – Key Facts 5
Zhejiang Huahai Pharmaceutical Co Ltd – Key Employees 6
Zhejiang Huahai Pharmaceutical Co Ltd – Key Operational Employees 7
Zhejiang Huahai Pharmaceutical Co Ltd – Major Products and Services 8
Zhejiang Huahai Pharmaceutical Co Ltd – History 9
Zhejiang Huahai Pharmaceutical Co Ltd – Company Statement 10
Zhejiang Huahai Pharmaceutical Co Ltd – Locations And Subsidiaries 11
Head Office 11
Other Locations & Subsidiaries 11
Section 2 – Company Analysis 13
Company Overview 13
Zhejiang Huahai Pharmaceutical Co Ltd – Business Description 14
Zhejiang Huahai Pharmaceutical Co Ltd – Corporate Strategy 15
Zhejiang Huahai Pharmaceutical Co Ltd – SWOT Analysis 16
SWOT Analysis – Overview 16
Zhejiang Huahai Pharmaceutical Co Ltd – Strengths 16
Zhejiang Huahai Pharmaceutical Co Ltd – Weaknesses 17
Zhejiang Huahai Pharmaceutical Co Ltd – Opportunities 18
Zhejiang Huahai Pharmaceutical Co Ltd – Threats 19
Zhejiang Huahai Pharmaceutical Co Ltd – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Zhejiang Huahai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 28
Zhejiang Huahai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 29
Zhejiang Huahai Pharmaceutical Co Ltd, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Dec 11, 2018: FDA issues warning letter to Zhejiang Huahai Pharmaceutical involved in valsartan recall 31
Nov 29, 2018: USFDA issues Warning Letter to Zhejiang Huahai Pharmaceutical 35
Oct 15, 2018: EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU Share 36
Oct 02, 2018: Information update – Health Canada finds Zhejiang Huahai Pharmaceuticals site non-compliant with requirements for the manufacture of drug ingredients 37
Sep 13, 2018: Update on review of valsartan medicines 38
Section 6 – Appendix 39
Methodology 39
Ratio Definitions 39
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Zhejiang Huahai Pharmaceutical Co Ltd, Key Facts 5
Zhejiang Huahai Pharmaceutical Co Ltd, Key Employees 6
Zhejiang Huahai Pharmaceutical Co Ltd, Key Operational Employees 7
Zhejiang Huahai Pharmaceutical Co Ltd, Major Products and Services 8
Zhejiang Huahai Pharmaceutical Co Ltd, History 9
Zhejiang Huahai Pharmaceutical Co Ltd, Subsidiaries 11
Zhejiang Huahai Pharmaceutical Co Ltd, Key Competitors 20
Zhejiang Huahai Pharmaceutical Co Ltd, Ratios based on current share price 21
Zhejiang Huahai Pharmaceutical Co Ltd, Annual Ratios 22
Zhejiang Huahai Pharmaceutical Co Ltd, Annual Ratios (Cont...1) 23
Zhejiang Huahai Pharmaceutical Co Ltd, Annual Ratios (Cont...2) 24
Zhejiang Huahai Pharmaceutical Co Ltd, Interim Ratios 26
Zhejiang Huahai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 28
Zhejiang Huahai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 29
Zhejiang Huahai Pharmaceutical Co Ltd, Recent Deals Summary 30
Currency Codes 39
Capital Market Ratios 39
Equity Ratios 40
Profitability Ratios 40
Cost Ratios 41
Liquidity Ratios 41
Leverage Ratios 42
Efficiency Ratios 42

List of Figures
Zhejiang Huahai Pharmaceutical Co Ltd, Performance Chart (2013 - 2017) 25
Zhejiang Huahai Pharmaceutical Co Ltd, Ratio Charts 27
Zhejiang Huahai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 28
Zhejiang Huahai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019 29

★海外企業調査レポート[Zhejiang Huahai Pharmaceutical Co Ltd (600521):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bangkok Bank Public Co Ltd:企業の戦略・SWOT・財務情報
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Jindal Steel & Power Ltd:企業の戦略・SWOT・財務情報
    Jindal Steel & Power Ltd - Strategy, SWOT and Corporate Finance Report Summary Jindal Steel & Power Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cofide (COF):企業概要、財務及び戦略的SWOT分析
    Summary COFIDE is a diversified business company. The company operates in the energy, automotive components, media and healthcare sectors. It generates electricity from gas, solar, and wind resources. COFIDE’s products include crude oil, natural gas, filters and suspension components. The company op …
  • Korea National Oil Corp:企業の戦略的SWOT分析
    Korea National Oil Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Bic Camera, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Bic Camera, Inc. Mergers and Ac …
  • Egalet Corp (EGLT):医療機器:M&Aディール及び事業提携情報
    Summary Egalet Corp (Egalet) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for pain and other conditions. Its product portfolio includes OXAYDO (oxycodone HCl, USP) tablets CII for the management of acute and chronic moderate to severe pain; SP …
  • Mirach Energy Limited (AWO):企業財務及び戦略的SWOT分析
    Summary Mirach Energy Limited (Mirach Energy), formerly China Petrotech Holdings Limited is an energy exploration and production company that explores and produces oil and gas. The company operates through it segments including oilfield services, and oil exploration and production. It also operates …
  • Wasko S.A. (WAS):企業の財務及び戦略的SWOT分析
    Summary Wasko S.A. (Wasko) is a technology company that designs and produces software, and provides IT services. The company’s products include power command, management of urban transport, fleet management, workflow management, documents and cases, management of industrial installations, access con …
  • Northbrook Energy, LLC:企業のM&A・提携動向(発電分野)
    Summary Northbrook Energy, LLC (Northbrook Energy), a subsidiary of Sintana Energy Inc. is a power producer that develops, owns and operates hydroelectric properties in North America. The company identifies and acquires risk-tolerable properties through private equity and project debt financing. It …
  • STRABAG SE:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' STRABAG SE Mergers and Acquisit …
  • Carbylan BioSurgery, Inc.(製薬・医療分野):企業M&A動向
    Summary Carbylan BioSurgery, Inc. (Carbylan) is a medical device company. The company develops and markets biomaterial based therapies and medicals for the treatment of osteoarthritis. Its products include Hydros and Hydros TA are used to treat knee osteoarthritis. The company’s Hydros is a viscosup …
  • Cia Iguacu de Cafe Soluvel:企業の戦略・SWOT・財務分析
    SummaryCia Iguacu de Cafe Soluvel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • Nisshin Seifun Group, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Nisshin Seifun Group, Inc. Merg …
  • EnteroMedics Inc (ETRM):企業のM&A・提携動向(医療機器分野)
    Summary EnteroMedics Inc (Enteromedics) is a medical device company that offers therapeutic products for gastrointestinal and metabolic diseases. The company designs and develops medical devices for the treatment of obesity and other disorders. It develops and provides VBLOC therapy used in the trea …
  • Jyoti Structures Ltd (JYOTISTRUC)-エネルギー分野:企業M&A・提携分析
    Summary Jyoti Structures Ltd (JSL) is a turnkey engineering, procurement, and construction (EPC) services provider that designs, tests, manufactures, sources, constructs, and supplies transmission lines, substations, and microwave towers. It designs HVDC and river crossing transmission towers, subst …
  • Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Gem Pharmaceuticals LLC (Gem Pharmaceuticals) is a clinical-stage biopharmaceutical company that develops proprietary anthracycline derivatives. The company’s pipeline products include GPX-150 for oncology, topical GPX-150 for inflammation, GPX 150 oral formulations and potency analogues pro …
  • TriMedx, LLC:企業概要及び戦略的SWOT分析
    TriMedx, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Dignity Health(製薬・医療分野):企業M&A動向
    Summary Dignity Health is a healthcare service provider. The company provides various medical and healthcare services to patients throughout the country. It offers physical, mental and spiritual services. Dignity Health’s services include urgent care, ambulatory surgery, home health, chronic care, p …
  • Immucor, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Immucor, Inc. Mergers and Acqui …
  • Davos Life Science Pte Ltd:企業の戦略・SWOT・財務情報
    Davos Life Science Pte Ltd - Strategy, SWOT and Corporate Finance Report Summary Davos Life Science Pte Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆